共 21 条
[1]
The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia[J] Elizabeth Kudlacz;Maryrose Conklyn;Catharine Andresen;Carrie Whitney-Pickett;Paul Changelian European Journal of Pharmacology 2008,
[2]
Targeting RET for thyroid cancer therapy[J] Cinzia Lanzi;Giuliana Cassinelli;Valentina Nicolini;Franco Zunino Biochemical Pharmacology 2008,
[3]
195 POSTER Pharmacogenomic analysis of the peripheral blood cell transcriptome in patients with advanced solid tumors treated with the mTOR inhibitor deforolimus (AP23573; MK 8669) in phase Ib studies[J] A. Rinaldi;I. Kwee;F. Bertoni;L. Viganò;D. Hess;N. Coceani;C. Sessa;V.M. Rivera;C.L. Bedrosian;C.V. Catapano EJC Supplements 2008,
[4]
Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study[J] Olivier Rixe;Ronald M Bukowski;M Dror Michaelson;George Wilding;Gary R Hudes;Oliver Bolte;Robert J Motzer;Paul Bycott;Katherine F Liau;James Freddo;Peter C Trask;Sinil Kim;Brian I Rini Lancet Oncology 2007,
[5]
Dasatinib: A tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome—positive acute lymphoblastic leukemia[J] Michael Steinberg Clinical Therapeutics 2007,
[6]
AG-013736; a novel inhibitor of VEGF receptor tyrosine kinases; inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging[J] Lisa J. Wilmes;Maria G. Pallavicini;Lisa M. Fleming;Jessica Gibbs;Donghui Wang;Ka-Loh Li;Savannah C. Partridge;Roland G. Henry;David R. Shalinsky;Dana Hu-Lowe;John W. Park;Teresa M. McShane;Ying Lu;Robert C. Brasch;Nola M. Hylton Magnetic Resonance Imaging 2007,
[7]
Pazopanib: A novel multitargeted tyrosine kinase inhibitor[J] Guru Sonpavde;Thomas E. Hutson Current Oncology Reports 2007,
[8]
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor; PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases[J] Lucy Lee;Sunil Sharma;Bruno Morgan;Peter Allegrini;Christian Schnell;Josef Brueggen;Robert Cozens;Mark Horsfield;Clemens Guenther;Will P. Steward;Joachim Drevs;David Lebwohl;Jeanette Wood;Paul
[9]
Characterization of AMN107; a selective inhibitor of native and mutant Bcr-Abl[J] Ellen Weisberg;Paul W. Manley;Werner Breitenstein;Josef Brüggen;Sandra W. Cowan-Jacob;Arghya Ray;Brian Huntly;Doriano Fabbro;Gabriele Fendrich;Elizabeth Hall-Meyers;Andrew L. Kung;Jürgen Mestan;George Q. Daley;Linda Callahan;Laurie Catley;Cara Cavazza;Azam Mohammed;Donna Neuberg;Renee D. Wright;D. Gary Gilliland;James D. Griffin Cancer Cell 2005,
[10]
Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes[J] Agnieszka Czechowska;Tomasz Poplawski;Jozef Drzewoski;Janusz Blasiak Chemico-Biological Interactions 2005,